Lymphoplasmacytic lymphoma primary prevention: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Lymphoplasmacytic lymphoma}} | {{Lymphoplasmacytic lymphoma}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{S.M.}} | ||
==Primary Prevention== | ==Primary Prevention== |
Revision as of 21:17, 13 February 2019
Lymphoplasmacytic lymphoma Microchapters |
Differentiating Lymphoplasmacytic Lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Lymphoplasmacytic lymphoma primary prevention On the Web |
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma primary prevention |
Risk calculators and risk factors for Lymphoplasmacytic lymphoma primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
Primary Prevention
Primary prevention of Waldenström macroglobulinemia depends on the type of risk factor causing the disease.[1]
Modifiable risk factors
Non-modifiable risk factors
- Age > 50
- Male gender
- Race - White
- Hereditary- Monoclonal gammopathy of undetermined significance
References
- ↑ Waldenström's macroglobulinemia. American Cancer Society. (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-prevention Accessed on November 11, 2015